AI assistant
Sending…
RESMED INC — Director's Dealing 2022
Dec 16, 2022
30071_dirs_2022-12-16_32c1ae45-d888-4918-8a44-a26b76b9951b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2022-12-15
Reporting Person: Farrell Michael J. (Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-15 | ResMed Common Stock | M | 5675 | $57.76 | Acquired | 442575 | Direct |
| 2022-12-15 | ResMed Common Stock | S | 5675 | $215.6348 | Disposed | 436900 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-15 | ResMed Common Stock Options | $57.76 | M | 5675 | Disposed | 2023-11-16 | ResMed Common Stock (5675) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| ResMed Common Stock | 4090 | Indirect |
Footnotes
F1: The transaction was conducted under a Rule 10b5-1 plan.
F2: This transaction was executed in multiple trades at prices ranging from $214.14 - $220.37. The price reported above reflects the weighted average sale price.
F3: Represents date options first became exercisable. Options vest 1/3 per year.
More from RESMED INC
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 10
Regulatory Filings
2026
Feb 9
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 3
Interim / Quarterly Report
2026
Jan 30
Regulatory Filings
2026
Jan 29
Director's Dealing
2026
Jan 9